On Friday, Galectin Therapeutics Inc (NASDAQ: GALT) was -6.81% drop from the session before settling in for the closing price of $5.58. A 52-week range for GALT has been $0.73 – $6.55.
A company in the Healthcare sector has dropped its sales by -23.89% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 35.53%. With a float of $44.30 million, this company’s outstanding shares have now reached $64.06 million.
Galectin Therapeutics Inc (GALT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Galectin Therapeutics Inc stocks. The insider ownership of Galectin Therapeutics Inc is 30.84%, while institutional ownership is 16.38%. The most recent insider transaction that took place on Nov 05 ’25, was worth 1,200. In this transaction President and CEO of this company sold 200 shares at a rate of $6.00, taking the stock ownership to the 832,592 shares. Before that another transaction happened on Nov 05 ’25, when Company’s Chief Financial Officer sold 600 for $6.00, making the entire transaction worth $3,600. This insider now owns 7,614 shares in total.
Galectin Therapeutics Inc (GALT) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.18 earnings per share (EPS) during the time that was better than consensus figure (set at -0.2) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
You can see what Galectin Therapeutics Inc (GALT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.44 million. That was better than the volume of 0.39 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 36.06%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 71.28%, which indicates a significant increase from 29.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.38 in the past 14 days, which was higher than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.90, while its 200-day Moving Average is $2.71. However, in the short run, Galectin Therapeutics Inc’s stock first resistance to watch stands at $5.59. Second resistance stands at $5.98. The third major resistance level sits at $6.25. If the price goes on to break the first support level at $4.93, it is likely to go to the next support level at $4.66. Assuming the price breaks the second support level, the third support level stands at $4.27.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
There are 64,479K outstanding shares of the company, which has a market capitalization of 333.11 million. As of now, sales total 0 K while income totals -47,050 K. Its latest quarter income was 0 K while its last quarter net income were -7,520 K.
